Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

From p. 20 of the last Q, filed on Nov. 20, 2023:
Recent Developments

The Company recently learned that Alfasigma is considering terminating further work under the License Agreement, although as of the date of this report, Alfasigma has not notified the Company of the termination of the License Agreement or a cessation of further work under the License Agreement.



Brilacidin is being studied by NIH/NIAID-affiliated and other independent researchers funded by US Government grants, as a potential broad-spectrum antifungal. We anticipate these studies to continue as long as researchers remain positive about the antifungal properties and therapeutic potential of Brilacidin and government funding is available.



On August 28, 2023, the Company announced a milestone in the development of BTL’s StingRay Laser System. At that time, BTL was in final preparations to submit its family of specially designed fiber optics for FDA clearance which BTL has since submitted.

IPIX owns 41% of this company :
https://www.beam-med.com/
Certification: The company is ISO13485:2016 certified

I like the silence combined with slow rise in price.